Clinical trials
catalyst calendar across sponsors →Studies where VOR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 observational
Held by 9 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, +4 more) · FINRA short interest 8.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseNCT07404865To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: Telitacicept · Drug: Placebo | Primary Sjogren's Disease | 250 | Dec 2028 | ≤ 865 d | 2026-08-10 |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: Telitacicept · Drug: Placebo | Generalized Myasthenia Gravis | 180 | May 2027 | ≤ 285 d | 2026-06-18 |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSNCT04849910Incidence of neutrophil engraftmentRandomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Lack of Funding | Biological: VOR33 · Drug: Mylotarg | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | 67 | 2025-05-28actual | — | 2025-07-29 |
| A Long-term Follow-up Study of Patients Who Received VOR33NCT05309733observationalLong term safety of VOR33 in patients who participated in a VOR33 study in terms of study product-related Adverse Events/Serious Adverse Events (AEs/SAEs). | — | Terminatedsponsor's stated reason: Lack of Funding | Genetic: VOR33 | Leukemia, Myeloid, Acute | 10 | 2025-05-28actual | — | 2025-07-29 |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell TransplantNCT05984199Incidence of dose-limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Lack of Funding | Biological: VCAR33 | Leukemia, Myeloid, Acute | 38 | 2025-05-28actual | — | 2025-07-29 |
| A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)NCT05306574SLE Responder Index (SRI-4)Randomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Business decision | Biological: Telitacicept, Placebo | Systemic Lupus Erythematosus | 91 | 2025-01-06actual | — | 2026-01-09 |
| A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)NCT06456567SLE Responder Index (SRI-4)Randomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Sponsor business decision | Biological: Telitacicept · Drug: Placebo | Systemic Lupus Erythematosus | 0 | 2025-01-02actual | — | 2026-01-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19